Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Autonomous & Electric Vehicles (DRIV) vs Novavax Inc (NVAX) Price & Performance

Global X Autonomous & Electric VehiclesTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Global X Autonomous & Electric Vehicles vs Novavax Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.81, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

DRIVNVAX
Sector
Sector/ThematicHealth
52-Week High
$42.53$11.19
52-Week Low
$25.23$6.22
Market Cap
$1.31B
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Autonomous & Electric Vehicles

DRIV trades at $36.14, up 1.6% today, with technical indicators showing a bullish trend supported by moving averages, though RSI suggests potential overbought conditions. The stock's support and resistance levels are tightly clustered around $35-$36. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by rising fuel prices and supportive policies, which may benefit DRIV's sector exposure.

The outlook for DRIV is positive due to favorable industry trends, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed, with technical strength offset by valuation concerns. Investors should weigh growth potential against execution risks in the evolving EV market.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Global X Autonomous & Electric Vehicles

DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.

Read more on DRIV

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX